The Discounted Cash Flow (DCF) valuation of Supernus Pharmaceuticals Inc (SUPN) is 43.39 USD. With the latest stock price at 43.99 USD, the upside of Supernus Pharmaceuticals Inc based on DCF is -1.4%.
Based on the latest price of 43.99 USD and our DCF valuation, Supernus Pharmaceuticals Inc (SUPN) is a sell. selling SUPN stocks now will result in a potential gain of 1.4%.
| Range | Selected | |
| WACC / Discount Rate | 5.5% - 6.9% | 6.2% |
| Long-term Growth Rate | 2.5% - 4.5% | 3.5% |
| Fair Price | 28.59 - 105.77 | 43.39 |
| Upside | -35.0% - 140.4% | -1.4% |